AbCellera Biologics (ABCL) EBITDA: 2019-2024
Historic EBITDA for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to -$165.5 million.
- AbCellera Biologics' EBITDA fell 55.10% to -$47.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$146.7 million, marking a year-over-year decrease of 193.55%. This contributed to the annual value of -$165.5 million for FY2024, which is 12.80% down from last year.
- Latest data reveals that AbCellera Biologics reported EBITDA of -$165.5 million as of FY2024, which was down 12.80% from -$146.7 million recorded in FY2023.
- AbCellera Biologics' 5-year EBITDA high stood at $156.8 million for FY2022, and its period low was -$165.5 million during FY2024.
- Moreover, its 3-year median value for EBITDA was -$146.7 million (2023), whereas its average is -$51.8 million.
- As far as peak fluctuations go, AbCellera Biologics' EBITDA skyrocketed by 5,478.47% in 2020, and later tumbled by 193.55% in 2023.
- AbCellera Biologics' EBITDA (Yearly) stood at $118.9 million in 2020, then rose by 29.29% to $153.7 million in 2021, then climbed by 2.02% to $156.8 million in 2022, then crashed by 193.55% to -$146.7 million in 2023, then decreased by 12.80% to -$165.5 million in 2024.